Study of Interleukin-2 and Chemotherapy in Colorectal Cancer
Author Information
Author(s): T.J. Hamblin, S. Sadullah, P. Williamson, J. Stevenson, R. Oskam, P. Palmer, C.R. Franks
Primary Institution: Royal Bournemouth Hospital
Hypothesis
Can recombinant interleukin-2 combined with 5-fluorouracil improve treatment outcomes in metastatic colorectal cancer?
Conclusion
The study found that 33% of patients achieved a partial response to the treatment regimen.
Supporting Evidence
- Five patients achieved a partial response, indicating some effectiveness of the treatment.
- Patients experienced manageable side effects, with only one requiring intensive care.
- The median survival for evaluable patients was 476 days.
Takeaway
Doctors tested a new treatment for cancer that combines two medicines, and some patients got better.
Methodology
Patients received a continuous infusion of rIL-2 followed by injections of 5FU, with response assessed through imaging.
Potential Biases
Potential biases due to the small number of patients and lack of a control group.
Limitations
The small sample size may limit the generalizability of the results.
Participant Demographics
16 patients, median age 61, with a mix of colon and rectal cancer.
Statistical Information
P-Value
p<0.05
Confidence Interval
11.8%-61.6%
Statistical Significance
p<0.05
Want to read the original?
Access the complete publication on the publisher's website